
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated strong financial performance in Q4, reflected by a 7% increase in share value in after-market trading and an improved operating margin forecast of at least 750 basis points, suggesting an operating margin exceeding 16%. The company is positioned for future growth through several positive drivers, including new product launches, accelerated adoption in heart and lung transplants, and strong international expansion. Furthermore, TransMedics is establishing a new standard of care in organ transplant therapy, which is expected to enhance value creation and sustain business momentum in the coming years.
Bears say
TransMedics Group Inc. has expressed a negative outlook for its operating margins, forecasting a decline of 250 basis points due to significant investments in its clinical pipeline and international infrastructure. The company experienced mixed results in its product and service revenues, with product revenues of $87.7 million falling short of consensus by approximately $1 million despite a year-over-year growth of 33.1%. Additionally, gross margins weakened, coming in at 58.1%, which is 230 basis points below target, highlighting the challenges the company faces in maintaining profitability amidst competitive pressures and potential adoption risks for its Organ Care System.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares